Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:17 PM
Ignite Modification Date:
2025-12-24 @ 5:17 PM
NCT ID:
NCT03539250
Eligibility Criteria:
Inclusion Criteria:
* Newly-diagnosed and confirmed histopathologic diagnosis of nasopharyngeal squamous cell carcinoma, types WHO II-III, Stage I-IVA (AJCC staging, 2017, 8th edition), treated with intensity-modulated radiotherapy.
* No head and neck surgery of the primary tumor or lymph nodes except for incisional or excisional biopsies.
* Age between 18 years and 70 years.
* Karnofsky score ≥80
* WBC≥ 4,000/ul, platelets≥ 100,000/ul; serum creatinine≤ 1.6 mg/dl or 24hr. calculated creatinine clearance ≥ 60ml/min.
* Must undergo pre-treatment evaluation of tumor extent and tumor measurement. Tumor may be measurable or evaluable.
* Signed study-specific consent form prior to study entry.
Exclusion Criteria:
* Stage IVB
* Evidence of distant metastases
* Previous irradiation for head and neck tumor ≤ 6 months prior to study entry
* Previous chemotherapy ≤ 6 months prior to study entry
* Patient is on other experimental therapeutic cancer treatment
* Other malignancy except non-melanoma skin cancer or a carcinoma not of head and neck origin and controlled at least 5 years
* Active untreated infection
* Major medical or psychiatric illness, which in the investigator's opinions, would interfere with either the completion of therapy and follow-up or with full and complete understanding of the risks and potential complications of the therapy
* Pregnant women
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT03539250
Study Brief:
Protocol Section:
NCT03539250